USPTO Examiner GHALI ISIS A D - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18708606LIQUID DRESSING FOR PROMOTING WOUND HEALINGMay 2024April 2025Allow1110YesNo
18640949MICRONIZED EGGSHELL MEMBRANE PARTICLES AND THE USE THEREOF TO PROMOTE THE HEALING OF WOUNDSApril 2024April 2025Allow1210YesNo
18613281PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEMarch 2024July 2024Allow400YesNo
18441957ENTERIC TABLET CONTAINING DIMETHYL FUMARATEFebruary 2024May 2025Abandon1510NoNo
18489631TOPICAL DRUG DELIVERY DEVICES AND METHODS OF USEOctober 2023June 2024Allow811YesNo
18472258KAOLIN-BASED HEMOSTATIC GAUZE AND PREPARATION METHOD THEREOFSeptember 2023March 2025Abandon1820NoNo
18345279GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERSJune 2023September 2024Abandon1401NoNo
18341748COMPOSITE MATERIAL FOR RAPID BLOOD CLOTTING AND PREPARATION METHOD THEREOFJune 2023April 2024Allow920YesNo
18116964REINFORCED POROUS COLLAGEN SHEETMarch 2023January 2024Allow1120YesNo
18172042INJECTABLE GELS COMPRISING CROSS-LINKED HYALURONIC ACID AND HYDROXYAPATITE, AND METHODS OF MANUFACTURING THEREOFFebruary 2023March 2025Abandon2511NoNo
18092761METHOD OF MAKING TRANSDERMAL AMPHETAMINE COMPOSITION WITH LOW LEVELS OF CARBAMATEJanuary 2023June 2025Allow2900YesNo
18080433METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASESDecember 2022April 2025Abandon2820YesNo
18062736WOUND CARE COVERINGDecember 2022September 2024Abandon2121NoNo
17943538SWELLABLE POLYMERIC MATERIALS AND USEFUL ARTICLES INCORPORATING SAMESeptember 2022August 2024Abandon2321NoNo
17835193Method for Adjusting the Release of Active Agent in a Transdermal Delivery SystemJune 2022April 2024Allow2210YesNo
17721853HOMEOSTATIC SINGLE LAYER DRESSINGApril 2022May 2024Abandon2560YesNo
17685818Transdermal Delivery SystemMarch 2022November 2024Allow3311YesNo
17682808ANHYDROUS HYDROCOLLOID MATRIX COMPRISING HOMOGENEOUSLY DISTRIBUTED ENCAPSULATED THERAPEUTIC AGENTSFebruary 2022April 2023Allow1321YesNo
17681064NON-CULTURED, PARTIALLY DIGESTED, CRYOPRESERVED CARTILAGE PRODUCTFebruary 2022February 2025Allow3621YesNo
17589262Multi-Day Patch for the Transdermal Administration of RotigotineJanuary 2022May 2025Abandon4021NoNo
17569862TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATEJanuary 2022November 2022Allow1011YesNo
17541491TRANSDERMAL DEVICE COMPRISING NSAID OR ANALGESIC PRODRUG MOLECULESDecember 2021May 2025Allow4121YesNo
17536986THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETIONNovember 2021September 2024Abandon3311NoNo
17523661PHARMACEUTICAL COMPOSITIONSNovember 2021August 2024Allow3421YesNo
17523814Sublingual Delivery for Mitigation of Side Effects Associated with Sildenafil CitrateNovember 2021March 2024Abandon2801NoNo
17505798MICROCELL SYSTEMS FOR DELIVERING BENEFIT AGENTSOctober 2021December 2023Allow2610YesNo
17603885TRANSDERMAL THERAPEUTIC SYSTEMOctober 2021June 2025Abandon4410NoNo
17482871Composition for the Transdermal Delivery of FentanylSeptember 2021November 2023Abandon2610NoNo
17441256ENTERIC TABLET CONTAINING DIMETHYL FUMARATESeptember 2021February 2024Abandon2940YesNo
17440097HERBICIDAL COMPOSITION AND METHOD FOR CONTROLLING WEEDSSeptember 2021May 2025Abandon4410NoNo
17471330SOLID FORMULATIONSeptember 2021November 2024Allow3821YesNo
17464616SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH TRAZODONESeptember 2021December 2023Abandon2701NoNo
17407982LIQUID HEMOSTATIC MEDICAL MATERIALAugust 2021January 2024Allow2911YesNo
17359120OPHTHALMIC COMPOSITIONSJune 2021October 2023Abandon2701NoNo
17417703COMPOSITIONS AND METHODS FOR TREATING BURNS, WOUNDS, AND SKIN DISORDERSJune 2021June 2025Abandon4811NoNo
17347256AMMONIA PAD WITH RELEASABLE SEALJune 2021March 2025Allow4531YesNo
17311379COMPOSITION COMPRISING CHICORY ROOT AND PEA CELL WALL FIBER FOR TREATING BRACHYSPIRA INFECTIONSJune 2021February 2025Allow4412YesNo
17337691COMPOSITIONS FOR CONTROLLING PHYTOPLANKTON CONTAMINATIONJune 2021February 2024Allow3220YesNo
17298745COMPOSITION COMPRISING ELECAMPANE EXTRACT FOR ALLEVIATING PREMENSTRUAL SYNDROME SYMPTOMJune 2021September 2024Abandon3910NoNo
17290780MEDICINE FOR TREATMENT OF PSORIASIS AND PRODUCTION METHOD THEREOFMay 2021October 2024Abandon4211NoNo
17279977EXTERNAL PREPARATIONMarch 2021August 2024Abandon4001NoNo
17196599METHODS OF TREATING UREA CYCLE DISORDERS AND MAPLE SYRUP URINE DISEASEMarch 2021November 2021Allow810YesNo
17196416PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOFMarch 2021September 2021Allow610YesNo
17274416TRANSDERMAL PATCHES FOR USE IN AURICULOTHERAPYMarch 2021August 2024Abandon4111NoNo
17179251PREVENTION AND TREATMENT OF INFECTIOUS DISEASE USING LOW CONCENTRATION HYPOCHLOROUS ACID SOLUTIONSFebruary 2021June 2025Abandon5221NoNo
17176203TASTE-MASKED PHARMACEUTICAL COMPOSITIONS WITH GASTROSOLUBLE PORE-FORMERSFebruary 2021March 2025Abandon4931NoNo
17172235WEARABLE LIPOSOMAL CANNABIDIOL TRANSDERMAL PATCHFebruary 2021September 2023Abandon3111NoNo
17147903ANTITOXIC FIBERS AND FIBROUS MEDIA AND METHODS FOR MANUFACTURING SAMEJanuary 2021August 2023Abandon3101NoNo
17130415STIMULUS-RESPONSIVE MICELLAR CARRIERDecember 2020November 2023Allow3421YesNo
17128293TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOFDecember 2020March 2023Abandon2610NoNo
17254104COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF HAEMORRHOIDSDecember 2020December 2024Abandon4831NoNo
17114890PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEDecember 2020May 2023Allow3011YesNo
17101005FIBRINOGEN COMPOSITION, METHOD AND WOUND ARTICLESNovember 2020October 2024Abandon4721NoNo
17056394SYNERGISTIC HEPATOPROTECTIVE COMPOSITIONNovember 2020December 2024Allow4921YesNo
17054975LONG LASTING ANTIMICROBIAL SURFACES BASED ON THE CROSS-LINKING OF NATURAL OILS WITHIN POLYMER NETWORKSNovember 2020March 2025Abandon5241YesNo
17073510Dermal Delivery DeviceOctober 2020April 2024Allow4221YesNo
17069758Transdermal DeliveryOctober 2020March 2023Abandon2910NoNo
17069571Transdermal DeliveryOctober 2020March 2023Abandon2910NoNo
17062379THERAPEUTIC ELASTIC BANDAGE FOR MODULATING THE ENDOCANNABINOID SYSTEMOctober 2020April 2024Abandon4221NoNo
17035705Antibacterial Cellulose Hydrogels and Preparation Method thereforSeptember 2020February 2024Abandon4120YesNo
16979577TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING NICOTINE AND SILICONE ACRYLIC HYBRID POLYMERSeptember 2020February 2023Abandon2901NoNo
16979572TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF BUPRENORPHINE COMPRISING A SILICONE ACRYLIC HYBRID POLYMERSeptember 2020February 2023Abandon2901NoNo
15733596TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A SILICONE ACRYLIC HYBRID POLYMERSeptember 2020September 2022Abandon2411NoNo
15733595TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A SILICONE ACRYLIC HYBRID POLYMERSeptember 2020September 2022Abandon2421YesNo
17007712Sealant Dressing with Protected Reactive ComponentsAugust 2020April 2025Allow5551YesNo
17005901TRANSDERMAL DEVICE COMPRISING ACETAMINOPHEN PRODRUGAugust 2020June 2022Allow2131YesNo
16975827METHYLPHENIDATE-CONTAINING TRANSDERMAL PATCHAugust 2020February 2024Abandon4150NoNo
16938234DERMAL PATCH FOR TRANSDERMAL ADMINISTRATION OF GHRELIN PATHWAY BLOCKERJuly 2020November 2023Abandon4020NoYes
16933836TRANSDERMAL DRUG DELIVERY METHOD AND SYSTEMJuly 2020November 2022Abandon2701NoNo
16961361SUSPENSION COMPOSITIONS OF MULTI-TARGET INHIBITORSJuly 2020May 2024Abandon4641YesNo
16925551TOPICAL FORMULATIONS WITH RESINIFERATOXIN NANOPARTICLES AND METHODSJuly 2020March 2023Allow3221YesNo
16913646METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASESJune 2020December 2022Abandon3030NoNo
16955437Biomedical FoamJune 2020September 2023Allow3921YesNo
16898120TOPICAL COMPOSITIONSJune 2020June 2021Allow1310YesNo
16898201GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERSJune 2020January 2021Allow810YesNo
16895150Napped Coated Wound DressingJune 2020June 2024Allow4841NoNo
16885429TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOFMay 2020February 2021Abandon810NoNo
16877957DEPOT FORMULATIONSMay 2020August 2023Abandon3921NoNo
16974343Powder for oral suspension containing lamotrigineMay 2020November 2023Abandon4231NoNo
15930141COMPOSITIONS FOR CONTROLLING PHYTOPLANKTON CONTAMINATIONMay 2020April 2021Allow1111YesNo
16863868PAIN RELIEVING SYSTEMApril 2020February 2023Abandon3311NoNo
16862469PAIN RELIEVER COMPOSITIONApril 2020May 2024Abandon4931NoNo
16861872Composition for the Transdermal Delivery of FentanylApril 2020October 2021Abandon1720NoNo
16759935Extended Wear-Time DressingApril 2020June 2023Allow3821YesNo
16859443DEPOT FORMULATIONSApril 2020January 2023Abandon3230YesNo
16857304APIXABAN TRANSDERMAL DELIVERY SYSTEM AND USES THEREOFApril 2020November 2022Abandon3120NoNo
16758951POWDER COSMETIC COMPOSITION CONTAINING STARCHApril 2020January 2023Abandon3320YesNo
16757290TRANSDERMAL DELIVERY SYSTEM CONTAINING A DOPAMINE AGONISTApril 2020November 2022Abandon3001NoNo
16756366COMPOSITION AND DEVICE FOR DELIVERY OF ACTIVE AGENTS TO SKIN SURFACESApril 2020May 2023Abandon3721NoNo
16837621SOLID COSMETIC COMPOSITION FOR EYE MAKE-UP INCLUDING FIBERApril 2020October 2023Abandon4340YesNo
16833209INHIBITING VIRAL AND BACTERIAL ACTIVITY USING LOW CONCENTRATION HYPOCHLOROUS ACID SOLUTIONSMarch 2020September 2022Abandon3060YesNo
16650961Glucocorticoid "Nintedanib" Particles and Their UseMarch 2020November 2023Allow4431YesNo
16827629GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERSMarch 2020October 2023Abandon4321YesYes
16820692MULTIPURPOSE IMPLANT WITH MODELED SURFACE STRUCTUREMarch 2020November 2022Abandon3220YesNo
16808117Laundry Additive for Providing Antimicrobial Effects to Fabrics and Interior Surfaces of Washing MachinesMarch 2020September 2021Abandon1811YesNo
16803532DERMAL DEVICE FOR ADMINISTRATION OF ONE OR MORE ACTIVE AGENTS TO THE SKINFebruary 2020May 2022Abandon2601NoNo
16641741TRANSDERMAL DELIVERY SYSTEM INCLUDING AN EMULSIFIERFebruary 2020March 2025Allow6051YesNo
16799578BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERYFebruary 2020June 2022Allow2711YesNo
16795497THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETIONFebruary 2020February 2022Abandon2410NoNo
16639810MICROPARTICLES CONTAINING FINASTERIDE AND PREPARATION METHOD THEREOFFebruary 2020April 2022Allow2611YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GHALI, ISIS A D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
72
Examiner Affirmed
53
(73.6%)
Examiner Reversed
19
(26.4%)
Reversal Percentile
41.0%
Lower than average

What This Means

With a 26.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
246
Allowed After Appeal Filing
51
(20.7%)
Not Allowed After Appeal Filing
195
(79.3%)
Filing Benefit Percentile
24.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GHALI, ISIS A D - Prosecution Strategy Guide

Executive Summary

Examiner GHALI, ISIS A D works in Art Unit 1611 and has examined 877 patent applications in our dataset. With an allowance rate of 25.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner GHALI, ISIS A D's allowance rate of 25.7% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GHALI, ISIS A D receive 3.31 office actions before reaching final disposition. This places the examiner in the 98% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GHALI, ISIS A D is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +38.4% benefit to allowance rate for applications examined by GHALI, ISIS A D. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 5.2% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 52.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 52.3% of appeals filed. This is in the 18% percentile among all examiners. Of these withdrawals, 36.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 53.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.